期刊文献+

MicroRNA-15a抑制骨髓瘤细胞生长及其机制研究 被引量:1

Growth Inhibition of Multiple Myeloma Cells Caused by MicroRNA-15a and Its Mechanisms
暂未订购
导出
摘要 目的:研究microRNA-15a(miR-15a)在多发性骨髓瘤(MM)细胞生长中的作用及可能机制。方法:慢病毒颗粒感染MM细胞株U266和RPMI8226,流式细胞术(FCM)分选获得稳定转染MM细胞株。CCK-8法检测miR-15a高表达前后MM细胞的增殖情况;AO/EB染色、Hoechst 33258荧光染色法及FCM检测miR-15a高表达前后MM细胞凋亡的情况;FCM检测miR-15a高表达前后MM细胞周期的情况;real-time PCR方法检测miR-15a高表达前后MM细胞miR-15a、BMI-1及BCL-2 mRNA的表达;Western blot方法检测miR-15a高表达前后MM细胞BMI-1蛋白表达。结果:获得高表达miR-15a的MM稳定转染细胞株。CCK-8结果显示miR-15a高表达可抑制M M细胞(U266和RPM I8226)的增殖;AO/EB、Hoechst 33258染色和FCM结果显示,miR-15a高表达可显著诱导MM细胞(U266和RPM I8226)的凋亡,U266和RPM I8226细胞高表达组与对照组细胞凋亡率分别为:90.52%vs37.08%,59.40%vs 44.17%;同时,miR-15a高表达可诱导MM细胞(U266和RPM I8226)G1期阻滞,G1期细胞分别为(41.50±0.64)%、(45.31±0.77)%。real-time PCR结果显示,在高表达miR-15a抑制骨髓瘤细胞生长的过程中BCL-2 mRNA表达显著降低,BMI-1 mRNA表达则没有改变,但是Western blot结果却显示BMI-1蛋白表达出现显著降低。结论:miR-15a高表达通过诱导骨髓瘤细胞周期阻滞和凋亡抑制骨髓瘤细胞生长,其机制涉及miR-15a在转录后水平对BMI-1、BCL-2基因的负调控。 Objective:To explore the effect and possible mechanisms of miR-15a on growth of multiple myeloma (MM) cells. Methods:MM cell lines (U266 and RPMI8226) were transfected by lentiviral particles. MM stable cell lines were selected and collected by flow cytometry (FCM). Proliferation of MM cells before and after miR-15a high expression was detected by CCK-8 method. Apoptosis of MM cells before and after miR-15a high expression was detected by AO/EB dying, Hoechst 33258 dying and FCM, respectively. Cell cycle of MM cells before and after miR- 15a high expression was detected by FCM. The expressions of miR-15a, BMI-1 and BCL-2 mRNA of MM cells before and after miR-15a high expression were detected by real-time PCR. The expressions of BMI-1 protein of MM cells before and after miR-15a high expression were detected by Western blot. Results:MM stable cell lines with miR-15a high expression was acquired. CCK-8 result showed that high expression of miR-15a could inhibit growth of MM cells (U266 and RPMI8226). AO/EB dying, Hoechst 33258 dying and FCM testing results showed that high expression of miR-15a could significantly induce apoptosis of MM cells (U266 and RPMI8226 ). The apoptosis rates of U266 and RPMI8226 cells in high expression group and control group were 90. 52% vs 37.08% and 59.40% vs 44. 17%, respectively. Meanwhile, FCM testing results showed that high expression of miR-15a could induce G1 arrest of MM cells( U266 and RPMI8226 ), which proportion of G1 phase were 41.50% ± 0.64%, 45.31%± 0.77%, respectively. Real-time PCR results showed that during the growth inhibition process of MM cells caused by miR-15a high expression, the expression of BCL-2 mRNA decreased, but there was no significant changes in the expression of BMI-1 mRNA, while the expression of BMI-1 protein decreased significantly. Conclusion: High expression of miR-15a can induce cell cycle arrest and apoptosis of MM cells, then inhibit their growth. The mechanisms may be related with the negative regulation of BMI-1 and BCL-2 genes in post-transcription level caused by miR-15a.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2015年第3期706-712,共7页 Journal of Experimental Hematology
基金 国家和福建省临床重点专科建设项目资助 国家自然科学基金青年科学基金资助项目(81201872) 福建省自然科学基金资助项目(2013J01308) 福建医科大学教授学术发展基金(JS11005)
关键词 microRNA-15a 骨髓瘤 U266细胞株 RPMI8226细胞株 细胞周期 细胞凋亡 BMI-1 BCL-2 miR-15a multiple myeloma U266 cell line RPMI 8226 cell line cell cycle apoptosis BMI-1 BCL-2
  • 相关文献

参考文献3

二级参考文献46

  • 1Kyle RA,Rajkumar SV. Multiple myelomB. Blood,2008,111 2962-2972.
  • 2Bleau AM, I-Iambardzumyan D, Ozawa T, et al. PTEN/PDK/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell, 2009,4 : 226-235.
  • 3Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and mieroRNAs. Drug Resist Updat, 2007, 10: 59-67.
  • 4Eckstein N, Servan K, Hildebrandt B, et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res ,2009,69 : 2996-3003.
  • 5Williams RT, den Besten W, Sherr CJ. Cytokine-dependent imatinib resistance in mouse BCR-ABL ~ , Aft-null lymphoblastic leukemia. Genes Dev,2007,21: 2283-2287.
  • 6Meads MB, Hazlehurst LA, Dalton WS. The bone man~w microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res,2008,14 : 2519-2526.
  • 7Podar K, Chauhan D, Anderson KC. Bone microenvironment and the identification of new targets for myeloma therapy. Leukemia, 2009,23 : 10-24.
  • 8Roorda BD, ter Elst A, Kamps WA, et al. Bone marrow-derived cells and tumor growth: contribution of bone marrow-derived ceils to tumor micro-environments with special focus on mesenchymal stem cells. Crit Rev Oncol Hematol,2009,69: 187-198.
  • 9Bisping G, Wenning D, Kropff M, et al. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t ( 4 ; 14 ) myeloma. Clin Cancer Res, 2009.15:520-531.
  • 10Abe M. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma~ Int J Hematol, 2011, 94:334-343.

共引文献20

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部